Home / Deep Research / Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease Deep Research Fallback

⚠️ Fallback MONDO:0004691

Autosomal Dominant Polycystic Kidney Disease Deep Research Fallback

Provider Attempts

  • 2026-05-08T16:24Z: Falcon deep-research was invoked directly with deep-research-client research for Autosomal dominant polycystic kidney disease (MONDO:0004691) because just research-disorder requires an existing YAML file. The command produced no output for approximately two minutes and was terminated.
  • 2026-05-08T16:27Z: OpenAI deep-research fallback was invoked with the same template and variables. The command produced no output for approximately 90 seconds and was terminated.

No provider-generated deep-research artifact was available. Curation therefore proceeded from exact, locally cached evidence and the structured ORPHA:730 record. No references_cache/*.md files were hand-created or hand-edited.

Evidence Scope Used For Curation

  • ORPHA:730 — structured Orphanet record for Autosomal dominant polycystic kidney disease. Used for the exact MONDO mapping, disease definition, disease-causing gene rows, and HPO phenotype-frequency rows.
  • PMID:40126492 — 2025 JAMA clinical review. Used for current prevalence, causal-gene proportions, major clinical frequencies (hepatic cysts, hypertension, intracranial aneurysm), progression to kidney replacement therapy, Mayo Imaging Classification, blood-pressure/sodium management, and tolvaptan effect size.
  • PMID:26718155 — clinical/pathogenesis review. Used for the PKD1/PKD2 loss-of-function framing and progressive renal-cyst phenotype.
  • PMID:26877954 — full-text mechanistic review on cyst growth, polycystins, and primary cilia. Used for the main pathophysiology chain: polycystin dosage loss at renal epithelial primary cilia, cilium-dependent cyst-promoting signal disinhibition, reduced calcium/increased cAMP signaling, epithelial proliferation, chloride-driven secretion, cyst expansion, fibrosis, parenchymal destruction, and renal failure.
  • PMID:23121377 / clinicaltrials:NCT00428948 — TEMPO 3:4 phase 3 tolvaptan trial. Used for the tolvaptan treatment entry, mechanism target, outcome evidence, and clinical-trial section.
  • PMID:16932388, PMID:10926175, and PMID:35253003 were reviewed as background scope for primary cilia, calcium homeostasis, Wnt/cAMP/Ras/MAPK signaling, two-hit pathogenesis, and JNK signaling, but were not cited directly in the YAML because the main cilium/cAMP pathway and clinical management claims were better supported by PMID:26877954, PMID:40126492, and PMID:23121377.

Curation Conclusions

ADPKD is best modeled as a renal epithelial ciliopathy in which reduced dosage or loss of PKD1/PKD2 polycystins and rarer polycystin-biogenesis/ciliary genes disrupt the polycystin receptor-channel complex at the primary cilium. The proximal consequence is loss of tonic suppression of a cilium-dependent cyst-promoting signal, accompanied by reduced cellular calcium signaling and increased intracellular cAMP. Elevated cAMP activates protein kinase A and supports epithelial proliferation plus chloride-driven fluid secretion, expanding epithelial-lined renal cysts. Progressive cyst expansion produces massive kidney enlargement, fibrosis/extracellular-matrix accumulation, destruction of renal parenchyma, declining GFR, elevated creatinine, chronic kidney disease, and kidney failure.

The curation prioritizes the major Orphanet clinical features: very frequent renal cysts, renal insufficiency, decreased GFR, elevated creatinine, and hepatic cysts; frequent hypertension, hematuria, chronic kidney disease, stage 5 chronic kidney disease, flank pain, albuminuria, and urinary electrolyte abnormalities; and clinically important occasional extrarenal/vascular features including nephrolithiasis, pyelonephritis, pancreatic cysts, mitral valve prolapse, aortic root aneurysm, cerebral artery dilatation/intracranial aneurysm, arachnoid cyst, and reproductive findings.

Treatment is represented by disease-modifying tolvaptan pharmacotherapy targeting the vasopressin/cAMP cyst-growth pathway, plus sodium restriction and blood-pressure targets as conservative management. Diagnosis is represented by MRI total-kidney-volume risk stratification through the Mayo Imaging Classification.